본문으로 건너뛰기
← 뒤로

Discovery and Preclinical Evaluations of Potent, Selective, and Allosteric Covalent WRN Inhibitors with Improved PK Properties.

1/5 보강
ACS medicinal chemistry letters 2026 Vol.17(2) p. 554-560
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
significant interest due to its implication as a synthetic lethal target in microsatellite instability-high (MSI-H) cancers
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
It also demonstrated favorable preclinical pharmacokinetic properties with superior plasma stability and exposure compared with VVD-214. Furthermore, compound showed statistically significant antitumor activity in the HCT116 xenograft mouse model with clear dose dependence.

Xu Z, Xiao Q, Liu Y, Jiang W, Liu L, Sun H, Yang X, Lu Z, Yan B, Long H, Zhang X

📝 환자 설명용 한 줄

Werner syndrome helicase (WRN) has received significant interest due to its implication as a synthetic lethal target in microsatellite instability-high (MSI-H) cancers.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Xu Z, Xiao Q, et al. (2026). Discovery and Preclinical Evaluations of Potent, Selective, and Allosteric Covalent WRN Inhibitors with Improved PK Properties.. ACS medicinal chemistry letters, 17(2), 554-560. https://doi.org/10.1021/acsmedchemlett.5c00787
MLA Xu Z, et al.. "Discovery and Preclinical Evaluations of Potent, Selective, and Allosteric Covalent WRN Inhibitors with Improved PK Properties.." ACS medicinal chemistry letters, vol. 17, no. 2, 2026, pp. 554-560.
PMID 41704373

Abstract

Werner syndrome helicase (WRN) has received significant interest due to its implication as a synthetic lethal target in microsatellite instability-high (MSI-H) cancers. Here we report the discovery of a novel allosteric covalent WRN inhibitor, compound , via structure-based medicinal design and pharmacokinetic optimization from VVD-214. Compound occupied a new cavity and formed an additional hydrogen bond with K894, thereby improving its activities. Compound exhibited high antiproliferation inhibitory activity against HCT116, an MSI-H colorectal cancer cell line. It also demonstrated favorable preclinical pharmacokinetic properties with superior plasma stability and exposure compared with VVD-214. Furthermore, compound showed statistically significant antitumor activity in the HCT116 xenograft mouse model with clear dose dependence.

같은 제1저자의 인용 많은 논문 (5)